Interim Report, 1 January – 31 March 2010

• Net sales were SEK 21.3 (17.5) m. • The loss after tax was SEK -26.2 (-30.2) m. • Earnings per share were SEK -1.25 (-1.45). • Cash flow from operating activities was SEK -32.0 (-41.2) m. • Cash and cash equivalents as of 31 March were SEK 184.1 (243.1) m. Comments from the CEO “The highlight for the first quarter was the launch of Xerclear™ in the home markets of Sweden and Finland through our own sales and marketing organization. This is a really exciting and important milestone for the company. An agreement was also concluded with Meda AB who will launch Xerclear™ in North America and the Xerese™ brand towards the end of this year and partnership discussions are also well advanced for Europe and other geographies. The company also completed an overhaul of its R&D portfolio and implemented a greatly improved portfolio management system. This has resulted in us prioritizing 9 projects, 6 of which are for infectious diseases. Medivir has also identified further infectious disease projects, which can be fast tracked due to Medivir’s expertise in this segment. In order to exploit our portfolio to its full potential and to ensure adequate resources for the commercial development of the company the Board of Directors of Medivir has resolved to conduct a rights offering, subject to approval by the Annual General Meeting” commented Ron Long Medivir’s CEO.